Ehave, Inc. Adds Published Child, Adolescent And Adult Psychiatrist To Its Medical Advisory Board
July 01, 2021 08:30 ET
|
Ehave
MIAMI, July 01, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, continues its ongoing...
Health Wizz Co-Founder, Dr. Nitin Desai, To Assist And Advise Ehave On Mental Health Analytical Platforms
June 29, 2021 08:30 ET
|
Ehave
MIAMI, June 29, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today Dr. Nitin...
“The Science Behind Using Psychedelics To Treat Mental Health Disorders And Addiction Is Compelling”
June 16, 2021 07:30 ET
|
OTC Stock Review
OTCStockReview.com News Commentary ATLANTA, June 16, 2021 (GLOBE NEWSWIRE) -- Jim Cramer discussed psychedelics on his June 15, 2021 program and said, “The science behind using psychedelics to...
Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics
May 20, 2021 06:30 ET
|
Ehave
MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH...
Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application
May 11, 2021 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...
Ehave, Inc. Announces Engagement of Legal Counsel to Advise on Launch of KetaDASH in Miami Metro Area and across United States; Ehave Creates Path to Revenue Stream
April 22, 2021 12:32 ET
|
Ehave
MIAMI, April 22, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the Company...
Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology
April 16, 2021 07:30 ET
|
Ehave
MIAMI, April 16, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to...
Global Psychedelic Drugs Market Report 2020: Market Size is Projected to Reach $10.75 Billion by 2027
March 18, 2021 06:38 ET
|
Research and Markets
Dublin, March 18, 2021 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs Market, By Drugs (LSD, Ecstasy, Phencyclidine, GHB, Ketamine, Ayahuasca, Psilocybin), Route of Administration (Oral, Injectable,...
Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB
March 03, 2021 08:30 ET
|
Ehave
MIAMI, March 03, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has...
Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
February 26, 2021 11:39 ET
|
Ehave
MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch...